1-8 of 8
Graham Jackson, MA, MB BS, FRCP, FRCPath, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outcomes of Transplant-Eligible Newly Diagnosed Ultra-High Risk Myeloma Patients Treated in the NCRI Myeloma XI Trial Indicate the Need for Early Treatment Stratification and Novel Treatment Approaches

Martin F. Kaiser, Matthew Jenner, MBBS, MRCP, FRCPath, David Cairns, MSc, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Andrea Paterson, Rebecca Mottram, BA, BSc, Faith E. Davies, MD, Mark T Drayson, MB ChB, PhD FRCPath, Roger G. Owen, MD, Gareth Morgan, MDPhDFRCP, Gordon Cook, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 604.
https://doi.org/10.1182/blood-2019-124819
Published: 2019
Journal Articles

Mutant TET2 Allele Dosage Affects Response to 5-Azacitidine in Acute Myeloid Leukemia

Friedrich Stoelzel, MD, Sarah Elizabeth Fordham, PhD BSc, Wei Yu Lin, PhD, Helen Blair, PhD, Leo Ruhnke, MD, Desireé Kunadt, MD, Brigitte Mohr, PhD, Claire Elstob, PhD, Daniel Allsop, MD, Devi Nandana, BSc, Emmanouela-Niki Soura, MPhil, Catherine Park, PhD, Mohd Fadly, PhD, Thahira Rahman, PhD, Olaf Heidenreich, Heidi Altmann, PhD, Gail Jones, MD, Tobias Menne, MD PhD, Manja Wobus, PhD, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Helen Marr, PhD, Kenan Onel, MD PhD, Manja Meggendorfer, PhD, Torsten Haferlach, MD, Martin Bornhäuser, MD, James M. Allan
Journal: Blood
Blood (2019) 134 (Supplement_1): 113.
https://doi.org/10.1182/blood-2019-123047
Published: 2019
Journal Articles

Title - Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); Long Term Second Primary Malignancy (SPM) Incidence in the Context of Lenalidomide Maintenance

John R Jones, MD, David Cairns, MSc, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Faith E. Davies, MD, Rachel Sigsworth, Matthew Jenner, MBBS, MRCP, FRCPath, Martin F. Kaiser, Rebecca Mottram, BA, BSc, Mark T Drayson, MB ChB, PhD FRCPath, Gordon Cook, Walter M Gregory, PhD, Roger G. Owen, MD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Gareth Morgan, MDPhDFRCP
Journal: Blood
Blood (2019) 134 (Supplement_1): 3132.
https://doi.org/10.1182/blood-2019-127469
Published: 2019
Journal Articles

Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (FiTNEss): A UK Myeloma Research Alliance Study, Myeloma XIV

David Cairns, MSc, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Kara-Louise Royle, MSc, Phillip Best, Jenny Bird, MD, Stella Bowcock, MD BA, FRCP, FRCPath, MA, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Bryony Dawkins, BA, MSc, Mark T Drayson, MB ChB, PhD FRCPath, Rowena Henderson, Matthew Jenner, MBBS, MRCP, FRCPath, John R Jones, MD, Martin F. Kaiser, Bhuvan Kishore, MB BS, MRCP, FRCPath, David Meads, Ba, MSc, PhD, Rebecca Mottram, BA, BSc, Neil K Rabin, Roger G. Owen, MD, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Gordon Cook
Journal: Blood
Blood (2019) 134 (Supplement_1): 3153.
https://doi.org/10.1182/blood-2019-126207
Published: 2019
Journal Articles

Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)

Matthew Jenner, MBBS, MRCP, FRCPath, Amy L Sherborne, PhD, Andrew Hall, Vallari Shah, Katrina Walker, Sidra Ellis, Kim Sharp, Amy Price, James Croft, MBBS, BSc, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Louise Flanagan, PhD, Mark T Drayson, MB ChB, PhD FRCPath, Ruth M De Tute, BSc,MSc, Roger G. Owen, MD, Guy Pratt, Gordon Cook, Sarah R Brown, PhD MSc, BSc, Martin F. Kaiser
Journal: Blood
Blood (2019) 134 (Supplement_1): 3162.
https://doi.org/10.1182/blood-2019-123547
Published: 2019
Journal Articles

Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial

Sarah Anne Bird, David Cairns, MSc, PhD, Faith E. Davies, MD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Gordon Cook, Mark T Drayson, MB ChB, PhD FRCPath, Walter M Gregory, PhD, Matthew Jenner, MBBS, MRCP, FRCPath, John R Jones, MD, Martin F. Kaiser, Roger G. Owen, MD, Nigel H. Russell, MD, Gareth Morgan, MDPhDFRCP, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath
Journal: Blood
Blood (2019) 134 (Supplement_1): 4374.
https://doi.org/10.1182/blood-2019-128041
Published: 2019
Journal Articles

Lenalidomide Maintenance Prolongs Progression-Free Survival and Does Not Impact the Aggressiveness of Clinical Relapse: Data from Long-Term Follow up of the Myeloma XI Trial

Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Faith E. Davies, MD, Kara-Louise Royle, MSc, David Cairns, MSc, PhD, Gordon Cook, Mark T Drayson, MB ChB, PhD FRCPath, Walter M Gregory, PhD, Matthew Jenner, MBBS, MRCP, FRCPath, John R Jones, MD, Martin F. Kaiser, Roger G. Owen, MD, Nigel H. Russell, MD, Gareth Morgan, MDPhDFRCP, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1889.
https://doi.org/10.1182/blood-2019-126103
Published: 2019
Journal Articles

Lenalidomide Induction and Maintenance Maximizes Outcome for Newly Diagnosed Transplant Eligible Myeloma Patients Irrespective of Risk Status: Long-Term Follow-up of the Myeloma XI Trial

Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, David Cairns, MSc, PhD, John R Jones, MD, Bhuvan Kishore, MB BS, MRCP, FRCPath, Mamta Garg, MD FRCP, FRCPath, Cathy Williams, MD MRCP, FRCPath, Kamaraj Karunanithi, MD FRCPath, Jindriska Lindsay, MD, MRCP, FRCPath, Nigel H. Russell, MD, Matthew Jenner, MBBS, MRCP, FRCPath, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Mark T Drayson, MB ChB, PhD FRCPath, Roger G. Owen, MD, Walter M Gregory, PhD, Martin F. Kaiser, Faith E. Davies, MD, Gareth Morgan, MDPhDFRCP
Journal: Blood
Blood (2019) 134 (Supplement_1): 1910.
https://doi.org/10.1182/blood-2019-126160
Published: 2019